Senores Pharmaceuticals

520.25
+2.10
(0.41%)
Market Cap
2,395.94 Cr
EPS
13.67
PE Ratio
40.70
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
665.00
52 Week Low
435.25
PB Ratio
3.03
Debt to Equity
1.28
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,667.50
#1 4,00,089.11
35.03
#1 49,887.20
12.06
#1 9,648
-18.99
40.71
6,530.00
1,73,350.98
79.22
8,184.00
0.89
1,600
23.05
59.09
1,473.20
1,18,977.83
22.51
26,520.70
14.17
4,155
30.28
46.34
3,135.00
1,06,102.65
54.96
10,785.70
11.59
1,656
10.91
40.96
1,248.30
1,04,165.06
#1 18.43
28,905.40
12.36
5,578
21.14
65.75
2,352.40
97,054.97
50.15
10,615.60
19.57
1,942
-10.91
37.13
926.40
93,217.52
20.02
19,831.50
13.82
3,831
-0.19
61.14
1,954.00
89,208.10
27.27
20,141.50
#1 19.94
1,936
#1 112.49
42.68
1,143.80
66,432.09
19.10
29,559.20
17.55
3,169
-0.50
42.85
31,135.00
66,159.70
46.07
6,097.20
10.80
1,201
27.83
58.62
Forecast
Actual
Growth Rate
Revenue Growth
457.18 %
Net Income Growth
289.29 %
Cash Flow Change
-1,739.81 %
ROE
-23.80 %
ROCE
-50.08 %
EBITDA Margin (Avg.)
-51.25 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Dec 2024
Mar 2025
Revenue
80
104
108
126
Expenses
64
80
77
95
EBITDA
16
24
31
31
Operating Profit %
19 %
22 %
25 %
17 %
Depreciation
3
4
4
5
Interest
3
3
6
5
Profit Before Tax
10
18
21
21
Tax
3
3
4
3
Net Profit
7
14
16
18
EPS in ₹
4.01
8.03
5.04
3.81

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
59
131
622
Fixed Assets
7
27
235
Current Assets
27
51
251
Capital Work in Progress
8
35
97
Investments
15
17
0
Other Assets
29
53
289
Total Liabilities
59
131
622
Current Liabilities
10
52
248
Non Current Liabilities
13
34
143
Total Equity
37
46
232
Reserve & Surplus
28
36
174
Share Capital
9
10
31

Cash Flow

Cash Flow
2022
2023
2024
Net Cash Flow
2
-3
13
Investing Activities
-24
-48
-54
Operating Activities
-10
-1
-20
Financing Activities
37
46
87

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
66.66 %
45.76 %
45.76 %
45.77 %
FIIs
0.00 %
5.51 %
4.25 %
4.17 %
DIIs
0.00 %
18.61 %
11.78 %
9.65 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
31.43 %
Others
33.34 %
2.23 %
9.49 %
8.97 %
No of Share Holders
177
43,707
43,707
37,653

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 483.75 541.05
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 530.80 498.50

Announcements

Appointment Of Internal Auditors For FY 2025-261 day ago
Board Meeting Outcome for Outcome Of Board Meeting Held On June 02 20251 day ago
Compliances-Reg.24(A)-Annual Secretarial Compliance6 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
Audited Standalone And Consolidated Financial Results For Quarter And Financial Year Ended March 31 2025May 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 16, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 16, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Intimation Regarding Changes In The Senior Management Personnel (SMP) Of The CompanyMay 15, 2025
Appointment Of Secretarial Auditor For A Period Of Five (5) Consecutive Years From FY 2025-26 To FY 2029-30May 15, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 15 2025.May 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025 And To Transact Other Business Matters.May 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 02, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 23, 2025
Update In Respect Of Our Intimations Dated March 11 2025 And March 12 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 22, 2025
Intimation For Change In Contact Details Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The Company.Apr 19, 2025
Intimation For Change In Corporate Identity Number (CIN) And Listing Status Of Senores Pharmaceuticals Limited (Company) On The Ministry Of Corporate Affairs (MCA) Portal.Apr 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of Corporate Guarantee.Apr 02, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Mar 20, 2025
Additional Disclosure In Respect Of Our Intimation Dated March 11 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient (API) Manufacturing Facility Of The CompanyFeb 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 20, 2025
Intimation For Change In The Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of The Company.Feb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2025
Integrated Filing (Financial)Jan 23, 2025
Appointment of Secretarial AuditorJan 23, 2025
Monitoring Agency Report for the quarter ended December 31 2024Jan 23, 2025
Statement Of Deviation/Variation If Any For The Quarter Ended December 31 2024.Jan 23, 2025
Media Release For Q3 And 9MFY25Jan 23, 2025

Technical Indicators

RSI(14)
Neutral
50.98
ATR(14)
Less Volatile
19.31
STOCH(9,6)
Neutral
56.73
STOCH RSI(14)
Neutral
69.49
MACD(12,26)
Bullish
2.71
ADX(14)
Weak Trend
10.23
UO(9)
Bearish
44.96
ROC(12)
Uptrend And Accelerating
4.87
WillR(14)
Neutral
-51.17

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
Mahindra Manulife Large & Mid Cap Fund Direct - Growth
509162
1.03%
-0.17%
-0.21%
Apr 2025
Bank of India Mid & Small Cap Equity & Debt Fund Direct-Growth
205740
0.95%
-0.15%
-0.20%
Apr 2025
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
640883
0.61%
-0.13%
-0.14%
Apr 2025
Bank of India Multi Cap Fund Direct-Growth
130000
0.83%
-0.12%
-0.19%
Apr 2025
Bandhan BSE Healthcare Index Fund Direct-Growth
112
0.03%
-0.01%
0.03%
Apr 2025